Menu
2026 Session

Budget Amendments - SB30 (Member Request)

View Budget Item
View Budget Item amendments

Chief Patron: Aird
Continue Support for Pharmaceutical Manufacturing to Develop a Fast-Acting Insulin

Item 101 #4s

Item 101 #4s

First Year - FY2027 Second Year - FY2028
Commerce and Trade
Economic Development Incentive Payments FY2027 $1,000,000 FY2028 $1,000,000 GF

Language
Page 99, line 21, strike "$79,409,579" and insert "$80,409,579".
Page 99, line 21, strike "$100,427,863" and insert "$101,427,863".

Page 102, after line 20, insert:

"S. Out of this appropriation, $1,000,000 the first year and $1,000,000 the second year from the general fund is provided to the Virginia Economic Development Partnership Authority (VEDP) to continue support for a non-profit operating a pharmaceutical manufacturing facility in developing a fast-acting insulin. Prior to any funds being disbursed, pursuant to the existing Memorandum of Understanding (MOU) between the non-profit and VEDP, the company shall demonstrate a match of non-state funds equal to the amount provided in this paragraph. At the conclusion of the project, the company shall be required to report to the authority on the: (i) jobs created as a result of the investment; (ii) estimated savings to residents of the Commonwealth from purchase of low-cost insulin; and, (iii) estimated potential savings to the Commonwealth as a self-insured employer from the availability of affordable insulin manufactured at a non-profit facility in Virginia. Any funding remaining at the end of the fiscal year 2028 shall be carried forward into the next fiscal year and reappropriated for the purposes described in this paragraph."



Explanation

(This amendment provides $1.0 million GF each year to continue support for a non-profit operating a pharmaceutical manufacturing facility that is developing a fast-acting insulin. The funding requires a dollar-to-dollar match.)